BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Korean Liver Cancer Association., National Cancer Center. 2018 Korean Liver Cancer Association-National Cancer Center Korea Practice Guidelines for the Management of Hepatocellular Carcinoma. Gut Liver 2019;13:227-99. [PMID: 31060120 DOI: 10.5009/gnl19024] [Cited by in Crossref: 90] [Cited by in F6Publishing: 90] [Article Influence: 90.0] [Reference Citation Analysis]
Number Citing Articles
1 Cho HJ, Baek GO, Seo CW, Ahn HR, Sung S, Son JA, Kim SS, Cho SW, Jang JW, Nam SW, Cheong JY, Eun JW. Exosomal microRNA-4661-5p-based serum panel as a potential diagnostic biomarker for early-stage hepatocellular carcinoma. Cancer Med 2020;9:5459-72. [PMID: 32537885 DOI: 10.1002/cam4.3230] [Cited by in Crossref: 7] [Cited by in F6Publishing: 10] [Article Influence: 7.0] [Reference Citation Analysis]
2 Cha SW, Sohn JH, Kim SH, Kim YT, Kang SH, Cho MY, Kim MY, Baik SK. Interaction between the tumor microenvironment and resection margin in different gross types of hepatocellular carcinoma. J Gastroenterol Hepatol 2020;35:648-53. [PMID: 31483517 DOI: 10.1111/jgh.14848] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
3 Kang TW, Kong SY, Kang D, Kang MW, Kim YK, Kim SH, Sinn DH, Kim YA, Choi KS, Lee ES, Woo SM, Back JH, Guallar E, Cho J. Use of Gadoxetic Acid-enhanced Liver MRI and Mortality in More than 30 000 Patients with Hepatocellular Carcinoma: A Nationwide Analysis. Radiology 2020;295:114-24. [PMID: 32013789 DOI: 10.1148/radiol.2020190639] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 5.0] [Reference Citation Analysis]
4 Fu Z, Li X, Zhong J, Chen X, Cao K, Ding N, Liu L, Zhang X, Zhai J, Qu Z. Lenvatinib in combination with transarterial chemoembolization for treatment of unresectable hepatocellular carcinoma (uHCC): a retrospective controlled study. Hepatol Int 2021;15:663-75. [PMID: 33877527 DOI: 10.1007/s12072-021-10184-9] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
5 Llovet JM, Villanueva A, Marrero JA, Schwartz M, Meyer T, Galle PR, Lencioni R, Greten TF, Kudo M, Mandrekar SJ, Zhu AX, Finn RS, Roberts LR; AASLD Panel of Experts on Trial Design in HCC. Trial Design and Endpoints in Hepatocellular Carcinoma: AASLD Consensus Conference. Hepatology 2021;73 Suppl 1:158-91. [PMID: 32430997 DOI: 10.1002/hep.31327] [Cited by in Crossref: 21] [Cited by in F6Publishing: 22] [Article Influence: 21.0] [Reference Citation Analysis]
6 Rho SY, Lee HW, Kim DY, Kim KS. Current Status of Therapeutic Choice and Feasibility for Patients with Hepatocellular Carcinoma Aged ≥ 70 Years: A Nationwide Cancer Registry Analysis. J Hepatocell Carcinoma 2021;8:321-32. [PMID: 33959557 DOI: 10.2147/JHC.S306507] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
7 Kudo M, Han KH, Ye SL, Zhou J, Huang YH, Lin SM, Wang CK, Ikeda M, Chan SL, Choo SP, Miyayama S, Cheng AL. A Changing Paradigm for the Treatment of Intermediate-Stage Hepatocellular Carcinoma: Asia-Pacific Primary Liver Cancer Expert Consensus Statements. Liver Cancer 2020;9:245-60. [PMID: 32647629 DOI: 10.1159/000507370] [Cited by in Crossref: 25] [Cited by in F6Publishing: 27] [Article Influence: 25.0] [Reference Citation Analysis]
8 Pennisi G, Celsa C, Giammanco A, Spatola F, Petta S. The Burden of Hepatocellular Carcinoma in Non-Alcoholic Fatty Liver Disease: Screening Issue and Future Perspectives. Int J Mol Sci 2019;20:E5613. [PMID: 31717576 DOI: 10.3390/ijms20225613] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 5.5] [Reference Citation Analysis]
9 Jeon SK, Lee JM, Joo I, Yoo J, Park JY. Comparison of guidelines for diagnosis of hepatocellular carcinoma using gadoxetic acid-enhanced MRI in transplantation candidates. Eur Radiol 2020;30:4762-71. [PMID: 32333148 DOI: 10.1007/s00330-020-06881-y] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
10 Kim HI, Lim J, Shim JH. Role of the alpha-fetoprotein response in immune checkpoint inhibitor-based treatment of patients with hepatocellular carcinoma. J Cancer Res Clin Oncol 2021. [PMID: 34459972 DOI: 10.1007/s00432-021-03727-y] [Reference Citation Analysis]
11 Ogasawara S, Ooka Y, Koroki K, Maruta S, Kanzaki H, Kanayama K, Kobayashi K, Kiyono S, Nakamura M, Kanogawa N, Saito T, Kondo T, Suzuki E, Nakamoto S, Tawada A, Chiba T, Arai M, Kato J, Kato N. Switching to systemic therapy after locoregional treatment failure: Definition and best timing. Clin Mol Hepatol. 2020;26:155-162. [PMID: 31937081 DOI: 10.3350/cmh.2019.0021n] [Cited by in Crossref: 12] [Cited by in F6Publishing: 13] [Article Influence: 12.0] [Reference Citation Analysis]
12 Becker-assmann J, Fard-aghaie MH, Kantas A, Makridis G, Reese T, Wagner KC, Petersen J, Buggisch P, Stang A, von Hahn T, Oldhafer KJ. Diagnostische und prognostische Bedeutung des α-Feto-Proteins beim hepatozellulären Karzinom. Chirurg 2020;91:769-77. [DOI: 10.1007/s00104-020-01118-6] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
13 Han X, Dong J, Liu Z, Wu B, Tian Y, Tan H, Cheng W. Quantitative dynamic contrast-enhanced ultrasound to predict intrahepatic recurrence of hepatocellular carcinoma after radiofrequency ablation: a cohort study. International Journal of Hyperthermia 2020;37:1066-73. [DOI: 10.1080/02656736.2020.1817576] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
14 Wei Y, Ye Z, Yuan Y, Huang Z, Wei X, Zhang T, Wan S, Tang H, He X, Song B. A New Diagnostic Criterion with Gadoxetic Acid-Enhanced MRI May Improve the Diagnostic Performance for Hepatocellular Carcinoma. Liver Cancer 2020;9:414-25. [PMID: 32999868 DOI: 10.1159/000505696] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 3.0] [Reference Citation Analysis]
15 Lu SD, Li L, Liang XM, Chen W, Chen FL, Fan LL, Ahir BK, Zhang WG, Zhong JH. Updates and advancements in the management of hepatocellular carcinoma patients after hepatectomy. Expert Rev Gastroenterol Hepatol 2019;13:1077-88. [PMID: 31648568 DOI: 10.1080/17474124.2019.1684898] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
16 Schwarze V, Rübenthaler J, Marschner C, Fabritius MP, Rueckel J, Fink N, Puhr-Westerheide D, Gresser E, Froelich MF, Schnitzer ML, Große Hokamp N, Afat S, Staehler M, Geyer T, Clevert DA. Advanced Fusion Imaging and Contrast-Enhanced Imaging (CT/MRI-CEUS) in Oncology. Cancers (Basel) 2020;12:E2821. [PMID: 33007933 DOI: 10.3390/cancers12102821] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 6.0] [Reference Citation Analysis]
17 Jang JW, Kim JS, Kim HS, Tak KY, Lee SK, Nam HC, Sung PS, Kim CM, Park JY, Bae SH, Choi JY, Yoon SK. Significance of TERT Genetic Alterations and Telomere Length in Hepatocellular Carcinoma. Cancers (Basel) 2021;13:2160. [PMID: 33946181 DOI: 10.3390/cancers13092160] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
18 Chen LT, Martinelli E, Cheng AL, Pentheroudakis G, Qin S, Bhattacharyya GS, Ikeda M, Lim HY, Ho GF, Choo SP, Ren Z, Malhotra H, Ueno M, Ryoo BY, Kiang TC, Tai D, Vogel A, Cervantes A, Lu SN, Yen CJ, Huang YH, Chen SC, Hsu C, Shen YC, Tabernero J, Yen Y, Hsu CH, Yoshino T, Douillard JY. Pan-Asian adapted ESMO Clinical Practice Guidelines for the management of patients with intermediate and advanced/relapsed hepatocellular carcinoma: a TOS-ESMO initiative endorsed by CSCO, ISMPO, JSMO, KSMO, MOS and SSO. Ann Oncol. 2020;31:334-351. [PMID: 32067677 DOI: 10.1016/j.annonc.2019.12.001] [Cited by in Crossref: 25] [Cited by in F6Publishing: 27] [Article Influence: 12.5] [Reference Citation Analysis]
19 Kwon Y, Kim JR, Park YM, Choi BK, Kim C, Young Kim H, Yoon M. Predicting survival time of Korean hepatocellular carcinoma patients using the Cox proportional hazards model: a retrospective study based on big data analysis. Eur J Gastroenterol Hepatol 2021;33:1001-8. [PMID: 33470702 DOI: 10.1097/MEG.0000000000002058] [Reference Citation Analysis]
20 Lee J, Shin IS, Yoon WS, Koom WS, Rim CH. Comparisons between radiofrequency ablation and stereotactic body radiotherapy for liver malignancies: Meta-analyses and a systematic review. Radiother Oncol 2020;145:63-70. [PMID: 31923711 DOI: 10.1016/j.radonc.2019.12.004] [Cited by in Crossref: 28] [Cited by in F6Publishing: 25] [Article Influence: 28.0] [Reference Citation Analysis]
21 Wu D, Yin YQ, Li Y, Zhang L, Jiang YH, Wang Z. CK2α causes stemness and chemotherapy resistance in liver cancer through the Hedgehog signaling pathway. Hepatobiliary Pancreat Dis Int 2021:S1499-3872(21)00173-9. [PMID: 34548224 DOI: 10.1016/j.hbpd.2021.09.003] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
22 Kim HY, Lampertico P, Nam JY, Lee HC, Kim SU, Sinn DH, Seo YS, Lee HA, Park SY, Lim YS, Jang ES, Yoon EL, Kim HS, Kim SE, Ahn SB, Shim JJ, Jeong SW, Jung YJ, Sohn JH, Cho YK, Jun DW, Dalekos GN, Idilman R, Sypsa V, Berg T, Buti M, Calleja JL, Goulis J, Manolakopoulos S, Janssen H, Jang MJ, Lee YB, Kim YJ, Yoon JH, Papatheodoridis GV, Lee JH. An artificial intelligence model to predict hepatocellular carcinoma risk in Korean and Caucasian patients with chronic hepatitis B. J Hepatol 2021:S0168-8278(21)02087-0. [PMID: 34606915 DOI: 10.1016/j.jhep.2021.09.025] [Reference Citation Analysis]
23 Jogi S, Varanai R, Bantu SS, Manne A. Selecting the first line treatment in non-metastatic hepatocellular carcinoma - comparing clinical practice guidelines. Oncol Rev 2020;14:515. [PMID: 33425223 DOI: 10.4081/oncol.2020.515] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
24 Lee SU, Yoon SM, Cheng JC, Kim TH, Kim BH, Park JH, Jung J, Tsai CL, Chiang Y, Park JW. Multi-Institutional Retrospective Study of Radiotherapy for Hepatocellular Carcinoma in the Caudate Lobe. Front Oncol 2021;11:646473. [PMID: 33718247 DOI: 10.3389/fonc.2021.646473] [Reference Citation Analysis]
25 Choi HH, Rodgers SK, Khurana A, Nelson LW, Kamaya A. Role of Ultrasound for Chronic Liver Disease and Hepatocellular Carcinoma Surveillance. Magn Reson Imaging Clin N Am 2021;29:279-90. [PMID: 34243917 DOI: 10.1016/j.mric.2021.05.005] [Reference Citation Analysis]
26 Gomari MM, Farsimadan M, Rostami N, Mahmoudi Z, Fadaie M, Farhani I, Tarighi P. CD44 polymorphisms and its variants, as an inconsistent marker in cancer investigations. Mutat Res Rev Mutat Res 2021;787:108374. [PMID: 34083044 DOI: 10.1016/j.mrrev.2021.108374] [Reference Citation Analysis]
27 Kudo M. A Paradigm Change in the Treatment Strategy for Hepatocellular Carcinoma. Liver Cancer 2020;9:367-77. [PMID: 32999864 DOI: 10.1159/000507934] [Cited by in Crossref: 4] [Cited by in F6Publishing: 7] [Article Influence: 4.0] [Reference Citation Analysis]
28 Lee JS, Choi HJ, Kim BK, Park JY, Kim DY, Ahn SH, Han KH, Baek SE, Chung YE, Park MS, Kim MJ, Rhee H, Kim SU. The Modified Response Evaluation Criteria in Solid Tumors (RECIST) Yield a More Accurate Prognoses Than the RECIST 1.1 in Hepatocellular Carcinoma Treated with Transarterial Radioembolization. Gut Liver 2020;14:765-74. [PMID: 32050313 DOI: 10.5009/gnl19197] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 6.0] [Reference Citation Analysis]
29 Cheng AL, Hsu C, Chan SL, Choo SP, Kudo M. Challenges of combination therapy with immune checkpoint inhibitors for hepatocellular carcinoma. J Hepatol. 2020;72:307-319. [PMID: 31954494 DOI: 10.1016/j.jhep.2019.09.025] [Cited by in Crossref: 69] [Cited by in F6Publishing: 75] [Article Influence: 69.0] [Reference Citation Analysis]
30 Lee YS, Ko E, Yoon EL, Jung YK, Kim JH, Seo YS, Yim HJ, Kim KH, Kwon SY, Yeon JE, Um SH, Byun KS. Multiplexed Proteomic Approach for Identification of Serum Biomarkers in Hepatocellular Carcinoma Patients with Normal AFP. J Clin Med 2020;9:E323. [PMID: 31979338 DOI: 10.3390/jcm9020323] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
31 Kim B, Won JH, Kim J, Kwon Y, Cho HJ, Huh J, Kim JK. Hepatic Arterial Infusion Chemotherapy for Advanced Hepatocellular Carcinoma: Radiologic and Clinical Factors Predictive of Survival. AJR Am J Roentgenol 2021;216:1566-73. [PMID: 33852336 DOI: 10.2214/AJR.20.23213] [Reference Citation Analysis]
32 Lee S, Kim SS, Chang DR, Kim H, Kim MJ. Comparison of LI-RADS 2018 and KLCA-NCC 2018 for noninvasive diagnosis of hepatocellular carcinoma using magnetic resonance imaging. Clin Mol Hepatol 2020;26:340-51. [PMID: 32492765 DOI: 10.3350/cmh.2020.0004] [Cited by in Crossref: 14] [Cited by in F6Publishing: 10] [Article Influence: 14.0] [Reference Citation Analysis]
33 Wu D, Ma Z, Ma D, Li Q. Long non-coding RNA maternally expressed gene 3 affects cell proliferation, apoptosis and migration by targeting the microRNA-9-5p/midkine axis and activating the phosphoinositide-dependent kinase/AKT pathway in hepatocellular carcinoma. Oncol Lett 2021;21:345. [PMID: 33747202 DOI: 10.3892/ol.2021.12606] [Reference Citation Analysis]
34 Kwan BS, Kim JH, Park SJ, Choe WH, Kwon SY, Yoo BC. Comparison of the efficacy and safety of direct-acting antiviral therapy with or without hepatitis C-related hepatocellular carcinoma. Korean J Intern Med 2021;36:292-304. [PMID: 32241083 DOI: 10.3904/kjim.2019.297] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
35 Kim J, Kang W, Sinn DH, Gwak GY, Paik YH, Choi MS, Lee JH, Koh KC, Paik SW. Substantial risk of recurrence even after 5 recurrence-free years in early-stage hepatocellular carcinoma patients. Clin Mol Hepatol 2020;26:516-28. [PMID: 32911589 DOI: 10.3350/cmh.2020.0016] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 8.0] [Reference Citation Analysis]
36 Gupta P, Soundararajan R, Patel A, Kumar-M P, Sharma V, Kalra N. Abbreviated MRI for hepatocellular carcinoma screening: A systematic review and meta-analysis. J Hepatol 2021;75:108-19. [PMID: 33548385 DOI: 10.1016/j.jhep.2021.01.041] [Cited by in Crossref: 6] [Cited by in F6Publishing: 8] [Article Influence: 6.0] [Reference Citation Analysis]
37 Yoo GS, Yu JI, Park HC, Hyun D, Jeong WK, Lim HY, Choi MS, Ha SY. Do Biliary Complications after Proton Beam Therapy for Perihilar Hepatocellular Carcinoma Matter? Cancers (Basel) 2020;12:E2395. [PMID: 32847035 DOI: 10.3390/cancers12092395] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
38 Llovet JM, Lencioni R. mRECIST for HCC: Performance and novel refinements. J Hepatol. 2020;72:288-306. [PMID: 31954493 DOI: 10.1016/j.jhep.2019.09.026] [Cited by in Crossref: 48] [Cited by in F6Publishing: 44] [Article Influence: 48.0] [Reference Citation Analysis]
39 Jang JW, Kim JS, Kim HS, Tak KY, Nam H, Sung PS, Bae SH, Choi JY, Yoon SK, Roberts LR. Persistence of intrahepatic hepatitis B virus DNA integration in patients developing hepatocellular carcinoma after hepatitis B surface antigen seroclearance. Clin Mol Hepatol 2021;27:207-18. [PMID: 33317255 DOI: 10.3350/cmh.2020.0115] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
40 Wan L, Dong DH, Wu XN, Ding HF, Lu Q, Tian Y, Zhang XF, Li W. Single Large Nodule (>5 cm) Prognosis in Hepatocellular Carcinoma: Kinship with Barcelona Clinic Liver Cancer (BCLC) Stage A or B? Med Sci Monit 2020;26:e926797. [PMID: 33060558 DOI: 10.12659/MSM.926797] [Reference Citation Analysis]
41 Lee JS, Kim BK, Kim SU, Park JY, Ahn SH, Seong JS, Han KH, Kim DY. A survey on transarterial chemoembolization refractoriness and a real-world treatment pattern for hepatocellular carcinoma in Korea. Clin Mol Hepatol 2020;26:24-32. [PMID: 31104456 DOI: 10.3350/cmh.2018.0065] [Cited by in Crossref: 15] [Cited by in F6Publishing: 13] [Article Influence: 7.5] [Reference Citation Analysis]
42 Su TH, Hsu SJ, Kao JH. Paradigm shift in the treatment options of hepatocellular carcinoma. Liver Int 2021. [PMID: 34515412 DOI: 10.1111/liv.15052] [Reference Citation Analysis]
43 Hwang SH, Hong SB, Park S, Han K, Park YN, Kim SY, Park MS. Subcentimeter hepatocellular carcinoma in treatment-naïve patients: noninvasive diagnostic criteria and tumor staging on gadoxetic acid-enhanced MRI. Eur Radiol 2021;31:2321-31. [PMID: 33044650 DOI: 10.1007/s00330-020-07329-z] [Reference Citation Analysis]
44 Jeong J, Park JG, Seo KI, Ahn JH, Park JC, Yun BC, Lee SU, Lee JW, Yun JH. Microvascular invasion may be the determining factor in selecting TACE as the initial treatment in patients with hepatocellular carcinoma. Medicine (Baltimore) 2021;100:e26584. [PMID: 34232206 DOI: 10.1097/MD.0000000000026584] [Reference Citation Analysis]
45 Rim CH, Cheng J, Huang W, Kimura T, Lee V, Zeng Z, Seong J. An evaluation of hepatocellular carcinoma practice guidelines from a radiation oncology perspective. Radiotherapy and Oncology 2020;148:73-81. [DOI: 10.1016/j.radonc.2020.03.027] [Cited by in Crossref: 9] [Cited by in F6Publishing: 4] [Article Influence: 9.0] [Reference Citation Analysis]
46 Rhee H, Cho E, Nahm JH, Jang M, Chung YE, Baek S, Lee S, Kim M, Park M, Han DH, Choi J, Park YN. Gadoxetic acid-enhanced MRI of macrotrabecular-massive hepatocellular carcinoma and its prognostic implications. Journal of Hepatology 2021;74:109-21. [DOI: 10.1016/j.jhep.2020.08.013] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 7.0] [Reference Citation Analysis]
47 Lee HA, Lee YS, Kim BK, Jung YK, Kim SU, Park JY, Kim JH, An H, Kim DY, Yim HJ, Ahn SH, Yeon JE, Byun KS, Han KH, Um SH, Seo YS. Change in the Recurrence Pattern and Predictors over Time after Complete Cure of Hepatocellular Carcinoma. Gut Liver 2021;15:420-9. [PMID: 32839362 DOI: 10.5009/gnl20101] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
48 Shin IS, Kim DG, Cha SW, Kang SH, Kim SH, Kim MY, Baik SK. Hepatocellular carcinoma in old age: are there any benefits of liver resection in old age? Ann Surg Treat Res 2020;99:65-71. [PMID: 32802811 DOI: 10.4174/astr.2020.99.2.65] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
49 Park S, Yoon WS, Rim CH. Indications of external radiotherapy for hepatocellular carcinoma from updated clinical guidelines: Diverse global viewpoints. World J Gastroenterol 2020; 26(4): 393-403 [PMID: 32063688 DOI: 10.3748/wjg.v26.i4.393] [Cited by in CrossRef: 16] [Cited by in F6Publishing: 7] [Article Influence: 16.0] [Reference Citation Analysis]
50 Zhong JH, Xing BC, Zhang WG, Chan AW, Chong CCN, Serenari M, Peng N, Huang T, Lu SD, Liang ZY, Huo RR, Wang YY, Cescon M, Liu TQ, Li L, Wu FX, Ma L, Ravaioli M, Neri J, Cucchetti A, Johnson PJ, Li LQ, Xiang BD. Repeat hepatic resection versus radiofrequency ablation for recurrent hepatocellular carcinoma: a retrospective multicentre study. Br J Surg 2021:znab340. [PMID: 34643677 DOI: 10.1093/bjs/znab340] [Reference Citation Analysis]
51 Kudo M. A New Treatment Option for Intermediate-Stage Hepatocellular Carcinoma with High Tumor Burden: Initial Lenvatinib Therapy with Subsequent Selective TACE. Liver Cancer 2019;8:299-311. [PMID: 31768341 DOI: 10.1159/000502905] [Cited by in Crossref: 15] [Cited by in F6Publishing: 19] [Article Influence: 7.5] [Reference Citation Analysis]
52 Oh JH, Goh MJ, Park Y, Kim J, Kang W, Sinn DH, Gwak GY, Choi MS, Lee JH, Koh KC, Paik SW, Paik YH. Different Performance of Liver Stiffness Measurement According to Etiology and Outcome for the Prediction of Liver-Related Events. Dig Dis Sci 2021;66:2816-25. [PMID: 32897445 DOI: 10.1007/s10620-020-06591-x] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
53 Chen LC, Lin HY, Hung SK, Chiou WY, Lee MS. Role of modern radiotherapy in managing patients with hepatocellular carcinoma. World J Gastroenterol 2021; 27(20): 2434-2457 [PMID: 34092968 DOI: 10.3748/wjg.v27.i20.2434] [Cited by in CrossRef: 3] [Cited by in F6Publishing: 1] [Article Influence: 3.0] [Reference Citation Analysis]
54 Song JH, Goh MJ, Park Y, Oh JH, Kang W, Sinn DH, Gwak GY, Paik YH, Choi MS, Lee JH, Koh KC, Paik SW. Prognosis of hepatocellular carcinoma patients diagnosed under regular surveillance: potential implications for surveillance goal. Scand J Gastroenterol 2021;56:274-80. [PMID: 33399022 DOI: 10.1080/00365521.2020.1866063] [Reference Citation Analysis]
55 Kim JM, Joh JW, Yi NJ, Choi GS, Kwon CHD, Lee KW, Suh KS. Living donor liver transplantation should be cautiously considered as initial treatment in recurrent hepatocellular carcinoma within the Milan criteria after curative liver resection. Ann Transl Med 2020;8:288. [PMID: 32355732 DOI: 10.21037/atm.2020.02.170] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
56 Rim CH, Lee HY, Kim JS, Kim H. Radiofrequency ablation and stereotactic body radiotherapy for hepatocellular carcinoma: should they clash or reconcile? Int J Radiat Biol 2021;97:111-9. [PMID: 33253598 DOI: 10.1080/09553002.2021.1857453] [Reference Citation Analysis]
57 Kim TH, Yoon JH, Lee JM. Emerging Role of Hepatobiliary Magnetic Resonance Contrast Media and Contrast-Enhanced Ultrasound for Noninvasive Diagnosis of Hepatocellular Carcinoma: Emphasis on Recent Updates in Major Guidelines. Korean J Radiol 2019;20:863-79. [PMID: 31132813 DOI: 10.3348/kjr.2018.0450] [Cited by in Crossref: 12] [Cited by in F6Publishing: 10] [Article Influence: 12.0] [Reference Citation Analysis]
58 Chae H, Sung PS, Choi H, Kwon A, Kang D, Kim Y, Kim M, Yoon SK. Targeted Next-Generation Sequencing of Plasma Cell-Free DNA in Korean Patients with Hepatocellular Carcinoma. Ann Lab Med 2021;41:198-206. [PMID: 33063681 DOI: 10.3343/alm.2021.41.2.198] [Reference Citation Analysis]
59 Kim Y, Lee HA, Lee JS, Jeon MY, Kim BK, Park JY, Kim DY, Ahn SH, Um SH, Seo YS, Kim SU. Association Between Curative Treatment after Transarterial Radioembolization and Better Survival Outcomes in Patients with Hepatocellular Carcinoma. Cancer Invest 2021;39:274-83. [PMID: 33356630 DOI: 10.1080/07357907.2020.1870126] [Reference Citation Analysis]
60 Lee SK, Jang JW, Nam H, Sung PS, Kim HY, Kwon JH, Lee SW, Song DS, Kim CW, Song MJ, Choi HJ, You YK, Bae SH, Choi JY, Yoon SK. Sorafenib for advanced hepatocellular carcinoma provides better prognosis after liver transplantation than without liver transplantation. Hepatol Int 2021;15:137-45. [PMID: 33496932 DOI: 10.1007/s12072-020-10131-0] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
61 Huang S, Wang S, Xie Y, He X, Yi X, Zhang J, Deng Z, Yin L. Application of NRS2002 in Preoperative Nutritional Screening for Patients with Liver Cancer. J Oncol 2021;2021:8943353. [PMID: 34518766 DOI: 10.1155/2021/8943353] [Reference Citation Analysis]
62 Kim DH, Choi JI. Current status of image-based surveillance in hepatocellular carcinoma. Ultrasonography 2021;40:45-56. [PMID: 33045812 DOI: 10.14366/usg.20067] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
63 Chang JW, Lee JS, Lee HW, Kim BK, Park JY, Kim DY, Ahn SH, Kim SU. No influence of hepatic steatosis on the 3-year outcomes of patients with quiescent chronic hepatitis B. J Viral Hepat 2021. [PMID: 34382730 DOI: 10.1111/jvh.13594] [Reference Citation Analysis]
64 Nam JY, Sinn DH, Bae J, Jang ES, Kim JW, Jeong SH. Deep learning model for prediction of hepatocellular carcinoma in patients with HBV-related cirrhosis on antiviral therapy. JHEP Rep 2020;2:100175. [PMID: 33117971 DOI: 10.1016/j.jhepr.2020.100175] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 4.0] [Reference Citation Analysis]
65 Park KH, Kim JH, Choe WH, Kwon SY, Yoo BC, Hwang JH, Park SW, Kim YJ, Park HS, Yu MH, Jeon HJ. Risk Factors for Liver Function Deterioration after Transarterial Chemoembolization Refractoriness in Child-Pugh Class A Hepatocellular Carcinoma Patients. Korean J Gastroenterol 2020;75:147-56. [PMID: 32209803 DOI: 10.4166/kjg.2020.75.3.147] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
66 Cho HJ, Eun JW, Baek GO, Seo CW, Ahn HR, Kim SS, Cho SW, Cheong JY. Serum Exosomal MicroRNA, miR-10b-5p, as a Potential Diagnostic Biomarker for Early-Stage Hepatocellular Carcinoma. J Clin Med 2020;9:E281. [PMID: 31968558 DOI: 10.3390/jcm9010281] [Cited by in Crossref: 25] [Cited by in F6Publishing: 27] [Article Influence: 25.0] [Reference Citation Analysis]
67 Sevco TJ, Masch WR, Maturen KE, Mendiratta-Lala M, Wasnik AP, Millet JD. Ultrasound (US) LI-RADS: Outcomes of Category US-3 Observations. AJR Am J Roentgenol 2021;217:644-50. [PMID: 34259543 DOI: 10.2214/AJR.20.23447] [Reference Citation Analysis]
68 Shanker MD, Moodaley P, Soon W, Liu HY, Lee YY, Pryor DI. Stereotactic ablative radiotherapy for hepatocellular carcinoma: A systematic review and meta-analysis of local control, survival and toxicity outcomes. J Med Imaging Radiat Oncol 2021. [PMID: 34396706 DOI: 10.1111/1754-9485.13309] [Reference Citation Analysis]
69 Lee J, Cho Y, Park S, Kim JW, Lee IJ. Skeletal Muscle Depletion Predicts the Prognosis of Patients With Hepatocellular Carcinoma Treated With Radiotherapy. Front Oncol 2019;9:1075. [PMID: 31681607 DOI: 10.3389/fonc.2019.01075] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
70 Cho HJ, Baek GO, Yoon MG, Ahn HR, Son JA, Kim SS, Cheong JY, Eun JW. Overexpressed Proteins in HCC Cell-Derived Exosomes, CCT8, and Cofilin-1 Are Potential Biomarkers for Patients with HCC. Diagnostics (Basel) 2021;11:1221. [PMID: 34359304 DOI: 10.3390/diagnostics11071221] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
71 Kim MS, Kim JH, Lee KH, Suh YJ. Incidental Gynecomastia on Thoracic Computed Tomography in Clinical Practice: Characteristics, Radiologic Features, and Correlation With Possible Causes in South Korean Men. Am J Mens Health 2020;14:1557988320908102. [PMID: 32456508 DOI: 10.1177/1557988320908102] [Reference Citation Analysis]
72 Hwang SH, Park MS, Park S, Lim JS, Kim SU, Park YN. Comparison of the current guidelines for diagnosing hepatocellular carcinoma using gadoxetic acid-enhanced magnetic resonance imaging. Eur Radiol 2021;31:4492-503. [PMID: 33409787 DOI: 10.1007/s00330-020-07468-3] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
73 Kim SW, Joo I, Kim H, Ahn SJ, Kang H, Jeon SK, Lee JM. LI-RADS treatment response categorization on gadoxetic acid-enhanced MRI: diagnostic performance compared to mRECIST and added value of ancillary features. Eur Radiol 2020;30:2861-70. [DOI: 10.1007/s00330-019-06623-9] [Cited by in Crossref: 21] [Cited by in F6Publishing: 17] [Article Influence: 21.0] [Reference Citation Analysis]
74 Bae JS, Lee JM, Jeon SK, Jang S. Comparison of MicroFlow Imaging with color and power Doppler imaging for detecting and characterizing blood flow signals in hepatocellular carcinoma.Ultrasonography. 2020;39:85-93. [PMID: 31759383 DOI: 10.14366/usg.19033] [Cited by in Crossref: 5] [Cited by in F6Publishing: 7] [Article Influence: 2.5] [Reference Citation Analysis]
75 Chang WI, Kim BH, Kim YJ, Yoon JH, Jung YJ, Chie EK. Role of radiotherapy in Barcelona Clinic Liver Cancer stage C hepatocellular carcinoma treated with sorafenib. J Gastroenterol Hepatol 2021. [PMID: 34693560 DOI: 10.1111/jgh.15722] [Reference Citation Analysis]
76 Byun J, Choi SH, Byun JH, Lee SJ, Kim SY, Won HJ, Shin YM, Kim PN. Comparison of the diagnostic performance of imaging criteria for HCCs ≤ 3.0 cm on gadoxetate disodium-enhanced MRI. Hepatol Int 2020;14:534-43. [PMID: 32314171 DOI: 10.1007/s12072-020-10040-2] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 4.0] [Reference Citation Analysis]
77 Kim TH, Koh YH, Kim BH, Kim MJ, Lee JH, Park B, Park J. Proton beam radiotherapy vs. radiofrequency ablation for recurrent hepatocellular carcinoma: A randomized phase III trial. Journal of Hepatology 2021;74:603-12. [DOI: 10.1016/j.jhep.2020.09.026] [Cited by in Crossref: 11] [Cited by in F6Publishing: 7] [Article Influence: 11.0] [Reference Citation Analysis]
78 Lee J, Sung PS, Yang H, Lee SK, Nam HC, Yoo SH, Lee HL, Kim HY, Lee SW, Kwon JH, Jang JW, Kim CW, Nam SW, Bae SH, Choi JY, Yoon SK. A Real-World Comparative Analysis of Lenvatinib and Sorafenib as a Salvage Therapy for Transarterial Treatments in Unresectable HCC. J Clin Med 2020;9:E4121. [PMID: 33371271 DOI: 10.3390/jcm9124121] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 5.0] [Reference Citation Analysis]
79 Yoo SH, Lim TS, Lee HW, Kim JK, Lee JS, Lee HW, Kim BK, Park JY, Kim DY, Ahn SH, Lee JI, Lee KS, Kim SU. Risk assessment of hepatocellular carcinoma and liver-related events using ultrasonography and transient elastography in patients with chronic hepatitis B. J Viral Hepat 2021. [PMID: 34185929 DOI: 10.1111/jvh.13560] [Reference Citation Analysis]
80 Radu P, Dufour JF. Changing TACTICS in intermediate HCC: TACE plus sorafenib. Gut 2020;69:1374-6. [PMID: 32169908 DOI: 10.1136/gutjnl-2020-320692] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
81 Kwak BJ, Park J, Kwon YK, Kwon JH, Yoon YC. Intraoperative radiofrequency ablation and distilled water peritoneal lavage for spontaneously ruptured hepatocellular carcinoma. Ann Surg Treat Res 2019;97:291-5. [PMID: 31824883 DOI: 10.4174/astr.2019.97.6.291] [Reference Citation Analysis]
82 Koh DM, Ba-Ssalamah A, Brancatelli G, Fananapazir G, Fiel MI, Goshima S, Ju SH, Kartalis N, Kudo M, Lee JM, Murakami T, Seidensticker M, Sirlin CB, Tan CH, Wang J, Yoon JH, Zeng M, Zhou J, Taouli B. Consensus report from the 9th International Forum for Liver Magnetic Resonance Imaging: applications of gadoxetic acid-enhanced imaging. Eur Radiol 2021;31:5615-28. [PMID: 33523304 DOI: 10.1007/s00330-020-07637-4] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
83 Choi HH, Rodgers SK, Fetzer DT, Wasnik AP, Millet JD, Morgan TA, Dawkins A, Gabriel H, Kamaya A. Ultrasound Liver Imaging Reporting and Data System (US LI-RADS): An Overview with Technical and Practical Applications. Acad Radiol 2020:S1076-6332(20)30354-8. [PMID: 32718745 DOI: 10.1016/j.acra.2020.06.004] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 3.0] [Reference Citation Analysis]
84 Liu YS, Lin XZ, Chen CY, Chiu YC, Kang JW, Tsai HW, Hung HY, Ho CM, Ou MC. Safety and effectiveness of new embolization microspheres SCBRM for intermediate-stage hepatocellular carcinoma: A feasibility study. Bosn J Basic Med Sci 2021;21:339-45. [PMID: 32841586 DOI: 10.17305/bjbms.2020.4770] [Reference Citation Analysis]
85 Yoon SM, Kim SY, Lim YS, Kim KM, Shim JH, Lee D, An J, Jung J, Kim JH, Lee HC. Stereotactic body radiation therapy for small (≤5 cm) hepatocellular carcinoma not amenable to curative treatment: Results of a single-arm, phase II clinical trial. Clin Mol Hepatol 2020;26:506-15. [PMID: 32646200 DOI: 10.3350/cmh.2020.0038] [Cited by in Crossref: 14] [Cited by in F6Publishing: 11] [Article Influence: 14.0] [Reference Citation Analysis]
86 Kim TH, Kim H, Joo I, Lee JM. Combined Hepatocellular-Cholangiocarcinoma: Changes in the 2019 World Health Organization Histological Classification System and Potential Impact on Imaging-Based Diagnosis. Korean J Radiol 2020;21:1115-25. [PMID: 32729276 DOI: 10.3348/kjr.2020.0091] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 4.0] [Reference Citation Analysis]
87 Geyer T, Rübenthaler J, Marschner C, von Hake M, Fabritius MP, Froelich MF, Huber T, Nörenberg D, Rückel J, Weniger M, Martens C, Sabel L, Clevert DA, Schwarze V. Structured Reporting Using CEUS LI-RADS for the Diagnosis of Hepatocellular Carcinoma (HCC)-Impact and Advantages on Report Integrity, Quality and Interdisciplinary Communication. Cancers (Basel) 2021;13:534. [PMID: 33572502 DOI: 10.3390/cancers13030534] [Reference Citation Analysis]
88 Li Y, Chen J, Weng S, Yan C, Ye R, Zhu Y, Wen L, Cao D, Hong J. Hepatobiliary phase hypointensity on gadobenate dimeglumine-enhanced magnetic resonance imaging may improve the diagnosis of hepatocellular carcinoma. Ann Transl Med 2021;9:55. [PMID: 33553348 DOI: 10.21037/atm.2020.02.38] [Reference Citation Analysis]
89 Oh H, Lee JH. Tivozanib in advanced inoperable hepatocellular carcinoma: considerations for patients with liver cirrhosis. Ann Transl Med 2020;8:1530. [PMID: 33313275 DOI: 10.21037/atm-20-3526] [Reference Citation Analysis]
90 Golfieri R, Bezzi M, Verset G, Fucilli F, Mosconi C, Cappelli A, Paccapelo A, Lucatelli P, Magand N, Rode A, De Baere T. Balloon-Occluded Transarterial Chemoembolization: In Which Size Range Does It Perform Best? A Comparison of Its Efficacy versus Conventional Transarterial Chemoembolization, Using Propensity Score Matching. Liver Cancer 2021;10:522-34. [PMID: 34721513 DOI: 10.1159/000516613] [Reference Citation Analysis]